Pemetrexed for Carcinoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
MD Anderson Cancer Center, Houston, TX
Carcinoma+3 More
Pemetrexed - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a Phase 2 open-label, single-arm trial for patients with MTAP-deficient advanced urothelial cancer who had received prior immunotherapy. This is a single site study at the University of Texas MD Anderson Cancer Center. This study will allow patients in second line of treatment for advanced urothelial ca or beyond. All patients must have been previously treated with immune checkpoint inhibitor (ICI) therapy as per current standard of care.

Eligible Conditions

  • Carcinoma
  • Transitional Cell, Carcinoma
  • Metastatic Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Carcinoma

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 and Number of Participants With Complete or Partial Response as their Best Overall Response per RECIST v1.1.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Carcinoma

Trial Design

1 Treatment Group

Pemetrexed Plus AB928 (Etrumadenant) Plus AB122 (Zimberelimab)
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Pemetrexed · No Placebo Group · Phase 2

Pemetrexed Plus AB928 (Etrumadenant) Plus AB122 (Zimberelimab)Experimental Group · 3 Interventions: Pemetrexed, Zimberelimab, Etrumadenant · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
2014
Completed Phase 3
~5260
Zimberelimab
2018
Completed Phase 1
~50
Etrumadenant
2018
Completed Phase 1
~130

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
Closest Location: MD Anderson Cancer Center · Houston, TX
Photo of MD Anderson Cancer Center 1Photo of MD Anderson Cancer Center 2Photo of MD Anderson Cancer Center 3
2004First Recorded Clinical Trial
74 TrialsResearching Carcinoma
521 CompletedClinical Trials

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,795,192 Total Patients Enrolled
256 Trials studying Carcinoma
37,378 Patients Enrolled for Carcinoma
Omar Alhalabi, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be at least 18 years of age at the time of screening.
Patients can be considered for second line of therapy or beyond (after ICI with PD-(L)1 agent)
Patients must have measurable disease by RECIST v1.1 and tumors of sufficient sizes for biopsy
You have liver function tests that are normal or only mildly abnormal.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.